Results for käänteiskopioijaentsyyminestäjä translation from Finnish to Bulgarian

Computer translation

Trying to learn how to translate from the human translation examples.

Finnish

Bulgarian

Info

Finnish

käänteiskopioijaentsyyminestäjä

Bulgarian

 

From: Machine Translation
Suggest a better translation
Quality:

Human contributions

From professional translators, enterprises, web pages and freely available translation repositories.

Add a translation

Finnish

Bulgarian

Info

Finnish

farmakoterapeuttinen ryhmä: nukleosidinen käänteiskopioijaentsyyminestäjä, atc- koodi:

Bulgarian

Фармакотерапевтична група - нуклеозиден аналог инхибитор на обратната транскриптаза, АТС код:

Last Update: 2012-04-10
Usage Frequency: 2
Quality:

Warning: This alignment may be wrong.
Please delete it you feel so.

Finnish

vaikutusmekanismi nevirapiini on hiv- 1: n ei- nukleosidinen käänteiskopioijaentsyyminestäjä.

Bulgarian

Механизъм на действие Невирапин е ненуклеозиден инхибитор на обратната транскриптаза (ННИОТ) на hiv- 1.

Last Update: 2012-04-10
Usage Frequency: 2
Quality:

Finnish

keskimääräinen altistuminen nukleosidisille käänteiskopioijaentsyyminestäjille oli kestänyt 257 viikkoa fosamprenaviiria ja ritonaviiria kahdesti vuorokaudessa saaneilla potilailla (79%: lla oli ≥ 3 aikaisempaa nukleosidista käänteiskopioijaentsyyminestäjää = nrti) ja 210 viikkoa potilailla, jotka saivat lopinaviiri/ ritonaviiria (64%: lla oli ≥ 3 aikaisempaa nukleosidista käänteiskopioijaentsyyminestäjää = nrti).

Bulgarian

Средната продължителност на предшестваща експозиция на nrtis е била 257 седмици за пациентите, приемащи фозампренавир с ритонавир два пъти дневно (при 79% са прилагани ≥ 3 nrtis в миналото) и 210 седмици за пациентите на лопинавир/ ритонавир (при 64% са прилагани ≥ 3 nrtis в миналото).

Last Update: 2012-04-10
Usage Frequency: 4
Quality:

Get a better translation with
8,045,019,399 human contributions

Users are now asking for help:



We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. Learn more. OK